Biological Sample Collection to Advance Research and Treatment: A Fight Osteosarcoma Through European Research and Euro Ewing Consortium Statement

Archive ouverte

Green, Darrell | van Ewijk, Roelof | Tirtei, Elisa | Andreou, Dimosthenis | Baecklund, Fredrik | Baumhoer, Daniel | Bielack, Stefan | Botchu, Rajesh | Boye, Kjetil | Brennan, Bernadette | Capra, Michael | Cottone, Lucia | Dirksen, Uta | Fagioli, Franca | Fernandez, Natalia | Flanagan, Adrienne | Gambarotti, Marco | Gaspar, Nathalie | Gelderblom, Hans | Gerrand, Craig | Gomez-Mascard, Anne | Hardes, Jendrik | Hecker-Nolting, Stefanie | Kabickova, Edita | Kager, Leo | Kanerva, Jukka | Kester, Lennart | Kuijjer, Marieke | Laurence, Valérie | Lervat, Cyril | Marchais, Antonin | Marec-Berard, Perrine | Mendes, Cristina | Merks, Johannes | Ory, Benjamin | Palmerini, Emanuela | Pantziarka, Pan | Papakonstantinou, Evgenia | Piperno-Neumann, Sophie | Raciborska, Anna | Roundhill, Elizabeth | Rutkauskaite, Vilma | Safwat, Akmal | Scotlandi, Katia | Staals, Eric | Strauss, Sandra | Surdez, Didier | Sys, Gwen | Tabone, Marie-Dominique | Toulmonde, Maud | Valverde, Claudia | van de Sande, Michiel | Wörtler, Klaus | Campbell-Hewson, Quentin | Mccabe, Martin | Nathrath, Michaela | Merks, Johannes H.M. | Sys, Gwen M.L. | van de Sande, Michiel A.J.

Edité par CCSD ; American Association for Cancer Research -

International audience. Abstract Osteosarcoma and Ewing sarcoma are bone tumors mostly diagnosed in children, adolescents, and young adults. Despite multimodal therapy, morbidity is high and survival rates remain low, especially in the metastatic disease setting. Trials investigating targeted therapies and immunotherapies have not been groundbreaking. Better understanding of biological subgroups, the role of the tumor immune microenvironment, factors that promote metastasis, and clinical biomarkers of prognosis and drug response are required to make progress. A prerequisite to achieve desired success is a thorough, systematic, and clinically linked biological analysis of patient samples, but disease rarity and tissue processing challenges such as logistics and infrastructure have contributed to a lack of relevant samples for clinical care and research. There is a need for a Europe-wide framework to be implemented for the adequate and minimal sampling, processing, storage, and analysis of patient samples. Two international panels of scientists, clinicians, and patient and parent advocates have formed the Fight Osteosarcoma Through European Research consortium and the Euro Ewing Consortium. The consortia shared their expertise and institutional practices to formulate new guidelines. We report new reference standards for adequate and minimally required sampling (time points, diagnostic samples, and liquid biopsy tubes), handling, and biobanking to enable advanced biological studies in bone sarcoma. We describe standards for analysis and annotation to drive collaboration and data harmonization with practical, legal, and ethical considerations. This position paper provides comprehensive guidelines that should become the new standards of care that will accelerate scientific progress, promote collaboration, and improve outcomes.

Suggestions

Du même auteur

The ENCCA‑WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24–25, 2015. Workshop Report

Archive ouverte | Kager, Leo | CCSD

International audience. This report summarizes the results of the 3rd Joint ENCCA-WP7, EuroSarc, EEC, PROVABES, and EURAMOS European Bone Sarcoma Network Meeting, which was held at the Children's Cancer Research Ins...

A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?

Archive ouverte | van Ewijk, Roelof | CCSD

International audience. Background/Objective: To analyze changes in recurrent/refractory osteosarcoma phase II trials over time to inform future trials in this population with poor prognosis.Methods: A systematic re...

Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)☆

Archive ouverte | Gaspar, Nathalie | CCSD

International audience. Background: We report results from the phase I dose-finding and phase II expansion part of a multicenter, open-label study of single-agent lenvatinib in pediatric and young adult patients wit...

Chargement des enrichissements...